HCV Reinfection and Cure: Retreatment and Harm Reduction Strategies That Work

When someone beats hepatitis C with direct-acting antivirals (DAAs), it’s tempting to think the fight is over. But for many, especially those still injecting drugs or living with ongoing exposure, the virus can come back. HCV reinfection isn’t a failure-it’s a reality. And the good news? It’s just as treatable the second, third, or even fourth time around.

Since DAAs hit the market in 2014, cure rates have soared past 95%. That’s not a guess-it’s what the CDC, WHO, and multiple clinical trials confirm. People are clearing the virus with just 8 to 12 weeks of oral pills. No injections. No side effects like fatigue or depression. No more waiting years for a liver transplant. But cure doesn’t mean immunity. The body doesn’t build lasting protection like it does with measles or chickenpox. So if you’re still sharing needles, using unsterile equipment, or having unprotected sex with someone who has HCV, you can get infected again.

Who Gets Reinfection? It’s Not Random

Reinfection doesn’t happen equally across populations. The highest risk is among people under 30 who inject drugs. Data from the HERO study shows they’re over three times more likely to get reinfected than older users. Methamphetamine users face nearly three times the risk too. And the first six months after treatment? That’s the danger zone. Half of all reinfections happen within that window.

Why? Because the virus spreads fast in environments where sterile needles aren’t available, and where stigma keeps people from seeking care. A 2024 survey by the Harm Reduction Coalition found that 68% of people who inject drugs were denied retreatment simply because they were still using drugs. That’s not just cruel-it’s scientifically wrong. The CDC says clearly: treat everyone, as often as needed. No exceptions.

How Is Reinfection Treated? It’s Simpler Than You Think

If you get HCV again, you don’t start over. You don’t need to prove you’ve "cleaned up" or show you’re "ready." You just need to get tested and start treatment. The same drugs that cured you the first time work again. For most cases of reinfection, the go-to combo is glecaprevir/pibrentasvir (Mavyret) for 8 weeks. It’s over 95% effective, even if you’ve been treated before.

But what if you relapsed? That’s different. A relapse means the virus came back after treatment ended, suggesting some virus slipped through. In those cases, doctors may switch to sofosbuvir/velpatasvir/voxilaprevir (Vosevi) for 12 weeks, or add ribavirin to the standard 16-week course. Resistance testing is recommended here-checking for mutations in the NS3 or NS5A genes. But for true reinfection? No testing needed. Just treat.

And here’s something new: in June 2025, the FDA approved Mavyret specifically for acute HCV infection-the kind that happens within weeks of exposure. That’s the first time any DAA has been labeled for early infection. It’s based on the PURGE-C trial, which found that 84% of people with new HCV infections were cured in just 4 weeks with the same drug. Not 95%. Not 98%. But 84%. And that’s still better than doing nothing.

Why Shorter Treatments Matter

Eight weeks is doable. Four weeks? That’s life-changing for people who bounce between shelters, jails, and streets. The PURGE-C trial didn’t just test a drug-it tested a new model. If you can treat someone on the same day they test positive, without requiring them to return for follow-ups, you’re more likely to actually cure them. And when you cure them, you stop transmission.

That’s why NIH launched PURGE-2 in April 2025, testing a 2-week course of glecaprevir/pibrentasvir. If it works, we could be looking at a world where HCV is treated in a single clinic visit. Imagine walking into a harm reduction center, getting tested, and walking out with a 28-day supply of pills. No referrals. No waiting. No stigma.

Harm Reduction Isn’t Optional-It’s the Foundation

You can’t cure HCV without addressing how it spreads. You can give someone 100 courses of DAAs, but if they’re still using dirty needles, they’ll get it again. And again. And again.

The data is clear:

• Needle-syringe programs that hand out at least 200 needles per person per year cut HCV transmission by 54%.
• Opioid agonist therapy (like methadone or buprenorphine) reduces new infections by half.
• When HCV treatment is offered right next to addiction services-like in a Boston MAT clinic-82% of people stick with treatment.

That’s not coincidence. That’s integration. People don’t choose between their liver and their addiction. They need both addressed at the same time. Yet in most places, you have to jump through hoops: first go to the addiction clinic, then wait for a referral to a liver specialist, then schedule a lab test, then wait for insurance approval. By then, the window for early treatment has closed.

As of August 2025, 32 U.S. states now allow "treatment on demand" for people who inject drugs. That means if you test positive for HCV, you can start treatment that same day-no pre-authorization, no waiting list, no judgment. That’s progress. But only 38% of countries worldwide offer needle programs at the level needed. That’s why global elimination is still a distant goal.

The Real Barrier Isn’t the Virus-It’s Stigma

On Reddit’s r/Hepatology, people who inject drugs talk about being told, "You’ll just get it again," or "Come back when you’re clean." That language isn’t just unhelpful-it’s dangerous. It tells people their health doesn’t matter unless they meet arbitrary standards of "worthiness."

But the science says otherwise. A 2024 study in JAMA Network Open found that retreatment for reinfection works just as well as treatment for first-time infection. No matter your history. No matter your lifestyle. If you have HCV, you deserve to be cured.

And here’s the kicker: curing HCV doesn’t just save your liver. It saves lives. HCV leads to cirrhosis, liver cancer, and death. But when you cure it, you reduce those risks by over 90%. You also stop passing it on. That’s treatment as prevention. It’s not theory. It’s happening in cities that have embraced integrated care.

What You Need to Do Now

If you’ve been cured of HCV and still have risk factors:

1. Get tested every 3 to 6 months. HCV RNA testing is the only way to catch reinfection early.
2. Use sterile needles every time. Needle exchanges are free and confidential.
3. Ask about opioid agonist therapy if you’re using opioids. It cuts your risk of HCV and overdose.
4. Don’t wait to get treated again. The sooner you start, the better the outcome.
5. Find a clinic that offers HCV care alongside addiction services. Co-location saves lives.

If you’re a provider:

• Treat everyone, no exceptions.
• Offer same-day treatment for acute HCV.
• Link patients to needle programs and MAT before they leave your office.
• Stop asking about "readiness." Ask: "When can we start?"

Looking Ahead

By 2030, the WHO wants to eliminate HCV as a public health threat. That means 90% fewer new infections and 80% fewer deaths. It’s possible-but only if we stop treating people like problems and start treating them like people.

The tools exist. The drugs work. The harm reduction strategies are proven. What’s missing? Political will. Funding. And the courage to say: everyone deserves to live without the fear of a virus they didn’t choose.

People who inject drugs aren’t a separate group from the rest of society. They’re our neighbors, our family members, our coworkers. And they deserve to live without the threat of a curable virus. The science is clear. The tools are here. Now it’s about who we choose to protect.